Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

EGFR Inhibitor ABT-414

Known as: ABT-414 
An epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon intravenous infusion, ABT-414 inhibits the… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background We recently reported an acceptable safety and pharmacokinetic profile of depatuxizumab mafodotin (depatux-m), formerly… Expand
Is this relevant?
Highly Cited
2017
Highly Cited
2017
Background The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety… Expand
  • figure 2
  • figure 3
Is this relevant?
2017
2017
PurposePatients with recurrent glioblastoma (rGBM) have a poor prognosis. Epidermal growth factor receptor (EGFR) gene… Expand
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2017
2017
2003Background: GBM is the most common malignant primary brain tumor in adults. Pts with rGBM have a poor prognosis. EGFR is… Expand
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Targeting tumor-overexpressed EGFR with an antibody–drug conjugate (ADC) is an attractive therapeutic strategy; however, normal… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2016
2016
2542Background: Recurrent GBM (rGBM) has dismal prognosis. Almost 50% GBM tumors harbor amplified (amp) EGFR. ABT-414 is a tumor… Expand
Is this relevant?
2015
2015
2016 Background: GBM remains almost universally fatal and new therapies are needed. The epidermal growth factor receptor (EGFR… Expand
Is this relevant?
2015
2015
2510 Background: Aberrant EGFR expression and signaling has been identified as a hallmark of cancer growth and survival. ABT-414… Expand
Is this relevant?
2014
2014
2021 Background: Patients (pts) with recurrent GBM have few treatment options and a very poor prognosis. GBM tumors often exhibit… Expand
Is this relevant?
2014
2014
BACKGROUND: Standard therapies have little effect on the poor survival rates of GBM. Abnormal epidermal growth factor receptor… Expand
Is this relevant?